Yong Wan
- Department of Pharmacology & Chemical Biology
SOM Endowed Chair Professor
- (404) 727-9947
- yong.wan@emory.edu
- Lab Website
Overview
The overarching goal of Wan laboratory, within the Department of Pharmacology and Chemical Biology at Emory University, is to define the molecular mechanisms of breast tumor initiation, progression, and metastasis, and to identify novel targets for therapeutic development. Particularly, the laboratory seeks to address how defects in the ubiquitin-proteasome system and other posttranslational modifiers such as protein methyltransferase, poly (ADP-ribose) polymerase and glycosyltransferase would result in deregulated tumor immune checkpoint function, genomic instability, abnormal cell cycle, and aberrant signaling that predispose otherwise normal cells to become cancerous tumor cells or promote cancer progression and metastasis.
Academic Appointment
- Professor, Pharmacology and Chemical Biology, Emory University School of Medicine
Research
Publications
-
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer.
Nat Commun Volume: 16 Page(s): 3552
04/15/2025 Authors: Chi JJ; Xie P; Cheng MH; Zhu Y; Cui X; Watson J; Zeng L; Uddin A; Nguyen H; Li L -
Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.
Adv Sci (Weinh) Volume: 12 Page(s): e2407494
03/01/2025 Authors: Cui X; Zhu Y; Zeng L; Zhang M; Uddin A; Gillespie TW; McCullough LE; Zhao S; Torres MA; Wan Y -
Ten-Step Total Synthesis of ()-Phaeocaulisin A Enabled by Cyclopropanol Ring-Opening Carbonylation.
J Am Chem Soc Volume: 146 Page(s): 32276 - 32282
11/27/2024 Authors: Liu C; Zhang M; Zeng L; Wan Y; Dai M -
Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs.
Adv Sci (Weinh) Volume: 11 Page(s): e2400757
10/01/2024 Authors: Zeng L; Zhu Y; Cui X; Chi J; Uddin A; Zhou Z; Song X; Dai M; Cristofanilli M; Kalinsky K -
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
J Clin Invest Volume: 134
03/26/2024 Authors: Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y -
CD8+ T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione/GPX4.
J Clin Invest Volume: 134
03/05/2024 Authors: Chen S; Fan J; Xie P; Ahn J; Fernandez M; Billingham LK; Miska J; Wu JD; Wainwright DA; Fang D -
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy.
Semin Cancer Biol Volume: 90 Page(s): 29 - 44
05/01/2023 Authors: Zeng L; Zhu Y; Moreno CS; Wan Y -
Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.
Sci Adv Volume: 9 Page(s): eadd6626
01/06/2023 Authors: Fu Z; Chen S; Zhu Y; Zhang D; Xie P; Jiao Q; Chi J; Xu S; Xue Y; Lu X -
CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response.
Cancers (Basel) Volume: 14
07/31/2022 Authors: Wavelet-Vermuse C; Odnokoz O; Xue Y; Lu X; Cristofanilli M; Wan Y -
Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.
Endocrinology Volume: 163
04/01/2022 Authors: Hophan SL; Odnokoz O; Liu H; Luo Y; Khan S; Gradishar W; Zhou Z; Badve S; Torres MA; Wan Y